Clinical trial NCT06935721: Pharmacokinetics of Y-4 Tablets With Pregabalin Capsules and Riluzole Tablets in Chinese Healthy Subject
Official title: An Open-label, Single-dose, Three-period Phase 1 Study to Compare the Pharmacokinetics of Y-4 Tablets With Pregabalin Capsules and Riluzole Tablets in Healthy Subjects Under Fasted Condition
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE1
Conditions: Healthy Male and Female Subjects
Keywords: phase I trial
Lead sponsor: Beijing Tiantan Hospital
Sponsor class: OTHER
Collaborators: name: Neurodawn Pharmaceutical Co., Ltd.
First posted: 2025-04-20
Enrollment: 10
Sex: ALL
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: SEQUENTIAL
Primary purpose: TREATMENT

Brief summary: Y-4 is a new fixed-dose combination drug product containing two active ingredients of pregabalin and riluzole.

The objective of the trial is to compare pharmacokinetic characteristics of Y-4 tablets with pregabalin capsules (Lyrica®) and riluzole tablets (Rilutek®) in Chinese healthy adult subjects after single oral administration under fasted condition.

Detailed description: This study will be an open-label, single-dose, three-period study in healthy adult subjects. A total of 10 subjects (half men and half women) will be enrolled in this study to be administered with Y-4 tablets, pregabalin capsules and riluzole tablets at three periods with a 7-day washout.

Periods and corresponding treatments are planned as following:

Period 1: Y-4 tablet, one tablet, 112.5 mg/28.125 mg (pregabalin/riluzole) Period 2: pregabalin capsule, one capsule, 75 mg/capsule Period 3: riluzole tablet, one tablet, 50 mg/tablet

Eligibility criteria: Inclusion Criteria:

1. Healthy adult male and female subjects, 18-45 years of age (including both ends).
2. Body weight ≥ 50 kg for male and ≥ 45 kg for female, body mass index (BMI) within the range of 19 - 28 kg/m2 (including both ends).
3. During the screening period, serum creatinine is within the normal range, or the standard creatinine clearance (CLcr) estimated by Cockcroft-Gault formula is ≥ 80 mL/min (for female subject, according to the calculation result × 0.85）.
4. Subjects who are able to understand and give their signed informed consent before any trial related procedures are performed.

Exclusion Criteria:

1. Subjects who are known to be allergic to pregabalin, riluzole or any excipients of Y-4 tablets (microcrystalline cellulose, Copovidone, croscarmellose sodium, colloidal silicon dioxide, magnesium stearate and Opadry amb Ⅱ), have allergic diseases or allergic constitution;
2. Subjects who have special requirements for diet and cannot follow the unified diet;
3. Physical examinations, vital signs, 12-lead electrocardiograms (ECG), chest X-ray (front position), laboratory tests (hematology, serum chemistry, coagulation test, urinalysis, etc.) and other screening tests found abnormalities that the researchers judged to be of clinical significance;
4. Subjects who have experienced angioedema in the past (such as swelling of the face, mouth (tongue, lips, and gums), and neck (pharynx and throat));
5. History of dizziness or vertigo with clinical significance, or disease of inner ear known to cause dizziness or vertigo;
6. QTcF \> 450 msec at the screening stage;
7. Diagnosed with insomnia, anxiety disorder, depression, epilepsy, or other serious mental disorders, and principal investigator determines that the subject is not suitable to participate in this trial;
8. Presence or history of hepatic or renal disease or any other condition known to interfere with the absorption, distribution, metabolism or excretion of medicines;
9. Subjects who drink too much tea, coffee and/or caffeine-containing beverages (more than 8 cups, 1 cup = 250 mL) every day within 3 months prior to screening, or disagree that any caffeine-containing beverages are prohibited during the trial;
10. Subjects who have consume any diet (food or beverage) rich in grapefruit, pitaya, mango and cranberry within 14 days prior to screening;
11. Subjects have disease history or current disease that may affect the safety evaluation of the subject or the internal process of the study drug, including the central nervous system, cardiovascular system, digestive system, respiratory system, urinary system, hematological system, immunology, psychiatry, metabolic abnormalities, gastrointestinal surgery (excluding appendicitis surgery), etc. In particular, there is a history of dysphagia or any gastrointestinal disease affecting drug absorption (including frequent nausea or vomiting caused by any cause) and eye diseases;
12. Donation or loss of blood equal to or in excess of 400 mL, or blood transfusion within 3 months prior to screening; or donation or loss of blood equal to or in excess of 200 mL within 1 month prior to screening;
13. Subjects who have taken any drugs known to be strong inhibitors or inducers of cytochrome P450 enzymes within 2 months prior to screening (such as inducers - barbiturates, carbamazepine, phenytoin, glucocorticoids, omeprazole; inhibitors - serotonin reuptake inhibitors (SSRI) antidepressants, cimetidine, diltiazem, macrolides, nitroimidazoles, sedative hypnotics, verapamil, fluoroquinolones, antihistamines); or subjects who have taken any prescription drugs, over-the-counter drugs and Chinese herbal medicine other than the above drugs within 14 days prior to screening;
14. Subjects who have taken central nervous system (CNS) depressants including opioids (pethidine hydrochloride, morphine, dihydromorphine hydrochloride, fentanyl, tramadol, etc), benzodiazepines (diazepam, flurazepam, clonazepam, oxazepam, chlordiazepine and triazolam etc), antiepileptic drugs (carbamazepine, sodium valproate, phenobarbital drugs etc) within 2 months prior to screening;
15. Subject with sleep apnea, or subjects with severe sleep snoring and daytime drowsiness;
16. Subjects with suicidal thoughts and behavior;
17. Subject participated in any other clinical trials within 3 months prior to screening;
18. Current or former drug users, or positive urine screen for drugs of abuse at screening (screening items include: dimethylenedioxyamphetamine, methamphetamine, ketamine, morphine, tetrahydrocannabinoid acid, cocaine);
19. Alcoholics or regular drinkers within 3 months prior to screening, that is, those who drink more than 14 units of alcohol per week (1 unit = 360 mL of beer or 45 mL of alcohol with 40% alcohol content or 150 mL of wine), or whose alcohol breath test results are greater than 0.0 mg/100 mL, or who cannot abstain from alcohol during the trial;
20. Smokers or those who cannot comply with the prohibition of smoking during the trial, or positive for cotinine screening;
21. Subjects who is positive for hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibody, syphilis antibody or human immunodeficiency virus (HIV) antibody;
22. Male subjects (or their partners) or female subjects have baby plans during the whole trial period and within 3 months after the end of the trial, or subjects are unwilling to take one or more non-drug contraceptive measures (such as complete abstinence, condoms, ligation, etc.) during the trial period;
23. Female subjects who have unprotected intercourse within 14 days prior to screening, or pregnant or lactating women;
24. Subjects with poor compliance or other factors unsuitable for participation in this trial.

Primary outcomes:
measure: adverse events
timeFrame: From the first day to the 25th± 1st day after the start of administration
measure: Incidence of subject getting abnormal results of laboratory tests after treatment
timeFrame: From the first day to the 25th± 1st day after the start of administration
measure: Incidence of subject getting abnormal results of 12-lead ECG after treatment
timeFrame: From the first day to the 25th± 1st day after the start of administration
measure: Incidence of subject getting abnormal results of vital signs after treatment.
timeFrame: From the first day to the 25th± 1st day after the start of administration
measure: Incidence of subject getting abnormal results of physical examinations after treatment.
timeFrame: From the first day to the 25th± 1st day after the start of administration
measure: Incidence of subject getting abnormal results of blood oxygen saturation after treatment
timeFrame: From the first day to the 25th± 1st day after the start of administration
measure: Incidence of subject getting abnormal results of C-SSSRS scale evaluation after treatment after treatment
timeFrame: From the first day to the 25th± 1st day after the start of administration
Secondary outcomes:
measure: Cmax
timeFrame: Up to 72 hours post-dose of each drug
measure: AUC0-t
timeFrame: Up to 72 hours post-dose of each drug
measure: AUC0-∞
timeFrame: Up to 72 hours post-dose of each drug
measure: Tmax
timeFrame: Up to 72 hours post-dose of each drug
measure: t1/2
timeFrame: Up to 72 hours post-dose of each drug
measure: λz
timeFrame: Up to 72 hours post-dose of each drug
measure: AUC_%Extrap
timeFrame: Up to 72 hours post-dose of each drug
measure: CL/F
timeFrame: Up to 72 hours post-dose of each drug
measure: Vz/F
timeFrame: Up to 72 hours post-dose of each drug
measure: MRT0-t
timeFrame: Up to 72 hours post-dose of each drug
measure: MRT0-∞
timeFrame: Up to 72 hours post-dose of each drug
Other outcomes:
Locations:
city: Beijing
country: China
facility: Beijing Tiantan Hospital, Capital Medical University Beijing
state: Beijing
Study officials:
References: